TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Nicotine Replacement for Alcoholic Smokers
Brief Summary: The overall objective of the study is to develop recommendations for treatment programs to help alcoholic smokers to stop smoking. A sample of 175 alcohol dependent cigarette smokers will be recruited from the community and treated in a 6-month outpatient alcohol and tobacco treatment program. The 175 patients will be divided into two groups. One group will receive an active nicotine patch and active nicotine gum. The other group will receive an active nicotine patch and placebo nicotine gum. Followup assessments will be conducted for 1-year from the beginning of treatment.


Options:
A: Arm Label: Nicotine patch plus placebo gum; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Placebo gum | Arm Label: Nicotine patch plus active gum; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Nicotine gum - Nicorette® | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy for alcohol and smoking cessation; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicoderm CQ nicotine patch; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Placebo gum; Assigned to Arm(s): Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicotine gum - Nicorette®; Assigned to Arm(s): Nicotine patch plus active gum
B: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
D: Arm Label: 1 concurrent smoking cessation; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral counseling plus contingency management | Arm Label: 2 deferred smoking cessation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral counseling plus contingency management | Intervention Type: BEHAVIORAL; Name: behavioral counseling plus contingency management; Assigned to Arm(s): 1 concurrent smoking cessation, 2 deferred smoking cessation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combination Nicotine Replacement for Alcoholic Smokers
Brief Summary: The overall objective of the study is to develop recommendations for treatment programs to help alcoholic smokers to stop smoking. A sample of 175 alcohol dependent cigarette smokers will be recruited from the community and treated in a 6-month outpatient alcohol and tobacco treatment program. The 175 patients will be divided into two groups. One group will receive an active nicotine patch and active nicotine gum. The other group will receive an active nicotine patch and placebo nicotine gum. Followup assessments will be conducted for 1-year from the beginning of treatment.


Options:
A: Arm Label: 8 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 24 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 52 weeks transdermal nicotine; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): 24 weeks transdermal nicotine, 52 weeks transdermal nicotine, 8 weeks transdermal nicotine
B: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
C: Arm Label: Nicotine patch plus placebo gum; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Placebo gum | Arm Label: Nicotine patch plus active gum; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Nicotine gum - Nicorette® | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy for alcohol and smoking cessation; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicoderm CQ nicotine patch; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Placebo gum; Assigned to Arm(s): Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicotine gum - Nicorette®; Assigned to Arm(s): Nicotine patch plus active gum
D: Arm Label: Nicotine Patch (4 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Nicotine Patch (8 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch (4 weeks), Nicotine Patch (8 weeks)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled study evaluating rosiglitazone: 4 mg tablets or placebo tablets administered orally twice daily for 12 weeks. The purpose of the study is to evaluate the efficacy and safety of rosiglitazone in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using a standard disease activity index. Calculation of the index requires patients to undergo flexible sigmoidoscopy at the start of the study and at week 12.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tralokinumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tralokinumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: 1. Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Basiliximab | Arm Label: 2. 40 mg Simulect; Type: EXPERIMENTAL; Interventions: Drug: Basiliximab | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): 1. Placebo, 2. 40 mg Simulect
C: Arm Label: Rosiglitazone; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled study evaluating rosiglitazone: 4 mg tablets or placebo tablets administered orally twice daily for 12 weeks. The purpose of the study is to evaluate the efficacy and safety of rosiglitazone in the treatment of mild to moderately active ulcerative colitis. Disease activity will be measured using a standard disease activity index. Calculation of the index requires patients to undergo flexible sigmoidoscopy at the start of the study and at week 12.


Options:
A: Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A
B: Arm Label: Rosiglitazone; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Beat Osteoporosis: Nourish and Exercise Skeletons (BONES)
Brief Summary: The Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project is an after-school program that includes weight loading physical activity, nutrition and bone health education, and calcium-rich snacks. The program is designed to improve bone health in early elementary school children.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Active play in after school programs (ASP) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active play in after school programs (ASP); Assigned to Arm(s): Intervention group
B: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Intervention Type: BEHAVIORAL; Name: Healthy Eating and Physical Activity; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
C: Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Little is known about acupuncture's efficacy for Irritable Bowel Syndrome (IBS). This trial uses a manualized acupuncture treatment format that closely follows clinical practice and allows flexibility in designing individualized treatments. In addition, a second parallel qualitative study will follow a subgroup of patients throughout the trial to explore the relationships between patients' interpretations and understandings (what anthropologists call "meaning") of irritable bowel and their response to treatment. Cortisol levels (an important stress hormone) will also be assessed.

This will be a 3-arm trial: Active acupuncture, placebo acupuncture, and wait list.


Options:
A: Arm Label: group 1; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: group 3; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: group 4; Type: SHAM_COMPARATOR; Interventions: Other: acupuncture | Intervention Type: OTHER; Name: acupuncture; Assigned to Arm(s): Group 2, group 1, group 3, group 4
B: Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): N/A
C: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: topiramate; Type: ACTIVE_COMPARATOR; Interventions: Drug: topiramate | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): topiramate
D: Arm Label: acupoint-meridian group; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: sham-acupoint group; Type: OTHER; Interventions: Other: acupuncture | Arm Label: waiting list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: acupuncture; Assigned to Arm(s): acupoint-meridian group, sham-acupoint group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Brief Summary: The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
C: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cediranib Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cediranib Placebo; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Brief Summary: The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.


Options:
A: Intervention Type: DRUG; Name: autologous human tumor-derived HSPPC-96; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
C: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm
D: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Brief Summary: The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.


Options:
A: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
B: Arm Label: Axitinib; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Axitinib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.
Brief Summary: The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 \[Temsirolimus\], administered intravenously \[IV\] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa \[IFN alfa\] subcutaneously \[SC\] three times per week \[TIW\], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Arm 1
D: Arm Label: RAD001 +BSC; Type: EXPERIMENTAL; Interventions: Drug: RAD001 | Arm Label: Placebo (plus BSC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RAD001; Assigned to Arm(s): RAD001 +BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (plus BSC)

Answer: B